ciprofloxacin has been researched along with oseltamivir in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Anikin, VB; Burakova, EA; Karpinskaya, LA; Laktionov, PP; Nazarkina, ZK; Saranina, IV; Silnikov, VN; Tikunova, NV; Zarubaev, VV | 1 |
| Helbig, G; Kyrcz-Krzemien, S; Pająk, J; Wieczorkiewicz, A; Woźniczka, K | 1 |
| Accinelli, C; Batisson, I; Fick, J; Grabic, R; Mencarelli, M; Saccà, ML | 1 |
| Chen, W; Xu, Z | 1 |
1 review(s) available for ciprofloxacin and oseltamivir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
7 other study(ies) available for ciprofloxacin and oseltamivir
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Biological evaluation of tetracationic compounds based on two 1,4-diazabicyclo[2.2.2]octane moieties connected by different linkers.
Topics: Anti-Bacterial Agents; Antifungal Agents; Antiviral Agents; Bacteria; Cations; Cell Survival; Dose-Response Relationship, Drug; Fungi; HEK293 Cells; Humans; Influenza A virus; Kinetics; MCF-7 Cells; Microbial Sensitivity Tests; Molecular Structure; Piperazines; Structure-Activity Relationship | 2016 |
Irreversible marrow aplasia after single course of 2-chlorodeoxyadenosine for hairy cell leukaemia preceding by A pandemic 2009-H1N1-associated pneumonia.
Topics: Amoxicillin; Anemia, Aplastic; Anti-Infective Agents; Antineoplastic Agents; Antiviral Agents; Aspergillosis; Bone Marrow; Ciprofloxacin; Cladribine; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Leukemia, Hairy Cell; Male; Oseltamivir; Pancytopenia; Pandemics; Pneumonia, Viral; Young Adult | 2011 |
Removal of oseltamivir (Tamiflu) and other selected pharmaceuticals from wastewater using a granular bioplastic formulation entrapping propagules of Phanerochaete chrysosporium.
Topics: Anti-Infective Agents; Biodegradation, Environmental; Ciprofloxacin; Erythromycin; Oseltamivir; Phanerochaete; Polymers; Sulfamethoxazole; Waste Disposal, Fluid; Water Pollutants, Chemical; Xenobiotics | 2010 |
Research on the pharmaceutical intellectual property protection and supervision of pharmacy administration.
Topics: Ciprofloxacin; Drug and Narcotic Control; Drug Industry; Humans; Intellectual Property; Internationality; Oseltamivir; Patents as Topic | 2017 |